While DOR-specific compounds have thus far not been effective for pain or depression in clinical trials despite their apparent promise in preclinical models, our discoveries point to the need for further inquiry into the potential role of these receptors in reward-related behaviors, and how changes to their function within reward circuits may underlie long-lasting impacts of ELA. The gene discussed is OPRD1; the disease is depressive symptom measurement.